Sector News

Shire considers takeover of Swiss biotech group Actelion -Sunday Times

June 8, 2015
Life sciences
(Reuters) – Pharmaceutical company Shire is considering a 12 billion pound ($18.32 billion) takeover of Actelion Ltd Europe’s biggest biotech firm, Britain’s Sunday Times newspaper reported, citing unnamed sources.
 
An informal approach by Shire was rebuffed several weeks ago, the newspaper said, citing financial industry sources.
 
Shire was willing to pay 160 Swiss francs a share for Actelion, the sources said, a hefty premium to the stock’s Friday closing price of 132 francs.
 
Asked by Reuters for comment, a spokeswoman for Shire said the company did not comment on speculation. An Actelion spokesman said the company did not comment on market rumours.
 
Earlier this year, Actelion raised its full-year guidance after strong sales of its new heart and lung drug helped its first-quarter earnings exceed analysts’ estimates.
 
At the time, the company’s chief executive told Reuters it had not received any outside interest to buy the company.
 
In April, Shire reported a better-than-expected 20 percent rise in first-quarter earnings, helped by the launch of the first drug to treat binge eating disorder.
 
($1 = 0.6549 pounds) (Reporting by William James; additional reporting by Joshua Franklin in Zurich; editing by Jane Merriman and Jason Neely)

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach